We are live on ! Find out more
VTVT icon

vTv Therapeutics
VTVT

42 hedge funds and large institutions have $33.7M invested in vTv Therapeutics in 2015 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

14% more funds holding

Funds holding: 37 → 42 (+5)

3% more capital invested

Capital invested by funds: $32.7M → $33.7M (+$1M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

7% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 14

Holders
42
Holders Change
+5
Holders Change %
+13.51%
% of All Funds
1.1%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
9
Increased
13
Reduced
14
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
OAM
Oxford Asset Management
United Kingdom
+$506K
2
State Street
State Street
Massachusetts
+$388K
3
Northern Trust
Northern Trust
Illinois
+$311K
4
Millennium Management
Millennium Management
New York
+$272K
5
BFA
BlackRock Fund Advisors
California
+$154K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$849K
2
PSC
Piper Sandler & Co
Minnesota
-$626K
3
Ameriprise
Ameriprise
Minnesota
-$226K
4
CS
Credit Suisse
Switzerland
-$202K
5
UBS AM
UBS AM
Illinois
-$182K
Name Holding Trade Value Shares
Change 		Change in
Stake
PPA
26
Parametric Portfolio Associates
Washington
$117K +$121K +431 New
California State Teachers Retirement System (CalSTRS)
27
California State Teachers Retirement System (CalSTRS)
California
$78K +$1.4K +5 +2%
TA
28
Teachers Advisors
New York
$45K +$46.6K +166 New
TCIM
29
TIAA CREF Investment Management
New York
$37K +$38.2K +136 New
New York State Common Retirement Fund
30
New York State Common Retirement Fund
New York
$29K +$30.3K +108 New
NFA
31
Nationwide Fund Advisors
Ohio
$22K +$16K +57 +248%
SO
32
STRS Ohio
Ohio
$13K – – –
Deutsche Bank
33
Deutsche Bank
Germany
$10K -$4.77K -17 -28%
JP Morgan Chase
34
JP Morgan Chase
New York
$8K +$8.14K +29 New
BNP Paribas Financial Markets
35
BNP Paribas Financial Markets
France
$7.37K -$561 -2 -7%
TRCT
36
Tower Research Capital (TRC)
New York
$7K -$89.8K -320 -92%
BJ
37
BlackRock Japan
Japan
$5K +$4.21K +15 +300%
Citigroup
38
Citigroup
New York
$3K +$2.81K +10 New
Bank of Montreal
39
Bank of Montreal
Ontario, Canada
$2K +$1.68K +6 New
Morgan Stanley
40
Morgan Stanley
New York
$1K -$849K -3,027 -100%
Bank of America
41
Bank of America
North Carolina
$1K -$9.82K -35 -85%
CS
42
Credit Suisse
Switzerland
– -$202K -773 Closed
VKH
43
Virtu KCG Holdings
New York
– -$151K -578 Closed
Susquehanna International Group
44
Susquehanna International Group
Pennsylvania
– -$143K -548 Closed
Royal Bank of Canada
45
Royal Bank of Canada
Ontario, Canada
– -$1.12K -4 -80%
Wells Fargo
46
Wells Fargo
California
– -$281 -1 Closed
1
2

VTVT Hedge Fund Activity: Q4 2015 in Review

42 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q4 2015, worth a combined $33.7M — up 3.1% from $32.7M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new VTVT positions and 4 closed out — a net gain of 5 holders — while 13 added to existing stakes and 14 trimmed.

The largest buyer was Oxford Asset Management, opening a new position worth an estimated $506K. The largest seller was Morgan Stanley, cutting an estimated $849K.

  • 42 institutional investors held vTv Therapeutics (VTVT) as of Q4 2015, up from 37 in Q3 2015.
  • Funds reported $33.7M of vTv Therapeutics stock for Q4 2015, up 3.1% quarter-over-quarter.
  • 9 funds opened new vTv Therapeutics positions in Q4 2015 and 4 closed out, a net change of +5 holders.
  • The largest vTv Therapeutics buyer in Q4 2015 was Oxford Asset Management, an estimated $506K added.
  • The largest vTv Therapeutics seller in Q4 2015 was Morgan Stanley, an estimated $849K sold.

Based on aggregated 13F filings for Q4 2015.